BridgeBio Pharma Inc (BBIO) Annual Income Statement (USD)
BBIO Quarterly Financials (USD)
Frequently Asked Questions About BridgeBio Pharma Inc (BBIO) Stock
BridgeBio Pharma Inc's (BBIO) last reported annual revenue was USD 221.90 Million.
BridgeBio Pharma Inc's (BBIO) annual revenue growth rate based on the revenue reported in the past 5 years is : 40.48%
BridgeBio Pharma Inc's(BBIO) is not profitable as of its last reported annual financials.
The net profit margin for BridgeBio Pharma Inc's(BBIO) from its laster reported year is -241.44%
The return on equity (ROE) for BridgeBio Pharma Inc's(BBIO) from its last reported annual financials is : -1789.67%
The return on assets (ROA) for BridgeBio Pharma Inc's(BBIO) from its last reported annual financials is : -47.83%
The return on invested capital (ROIC) for BridgeBio Pharma Inc's(BBIO) from its last reported annual financials is : -186.76%
The Debt to Equity ratio for BridgeBio Pharma Inc's(BBIO) from its last reported annual financials is : -118.10%
The dividend yield for BridgeBio Pharma Inc's(BBIO) from its laster reported year is 0.00%
BridgeBio Pharma Inc's(BBIO) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BBIO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
